BioSyent Inc. (TSXV:RX)
Canada · Delayed Price · Currency is CAD 15.75
-0.20 (-1.25%)
Aug 28, 2026, 3:50 PM EST
BioSyent Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 55.67 | 43.05 | 35.03 | 31.59 | 27.93 | 28.62 | |
Revenue Growth | 40.91% | 22.90% | 10.89% | 13.13% | -2.42% | 28.15% |
Cost of Revenue | 14.82 | 10.09 | 7.17 | 5.99 | 5.07 | 5.98 |
Gross Profit | 40.85 | 32.96 | 27.86 | 25.6 | 22.86 | 22.64 |
Selling, General & Admin | 26.65 | 21.77 | 18.67 | 18.13 | 15.88 | 14.45 |
Research & Development | -0.14 | - | - | - | - | - |
Operating Expenses | 27.63 | 21.77 | 18.67 | 18.13 | 15.88 | 14.45 |
Operating Income | 13.22 | 11.19 | 9.18 | 7.47 | 6.98 | 8.18 |
Interest Expense | -0.11 | -0.05 | -0.06 | -0.07 | -0.08 | -0.09 |
Interest & Investment Income | 0.68 | 0.81 | 1.09 | 1.13 | 0.53 | 0.16 |
Currency Exchange Gain (Loss) | 0.03 | 0.08 | - | - | - | - |
EBT Excluding Unusual Items | 13.82 | 12.03 | 10.21 | 8.53 | 7.43 | 8.25 |
Asset Writedown | - | - | -0.43 | - | - | - |
Other Unusual Items | - | - | - | - | - | 0.13 |
Pretax Income | 13.38 | 12.03 | 9.78 | 8.53 | 7.43 | 8.38 |
Income Tax Expense | 3.51 | 3.02 | 2.51 | 2.07 | 1.97 | 2.1 |
Net Income | 9.87 | 9.01 | 7.27 | 6.46 | 5.46 | 6.28 |
Net Income to Common | 9.87 | 9.01 | 7.27 | 6.46 | 5.46 | 6.28 |
Net Income Growth | 19.48% | 23.96% | 12.54% | 18.35% | -13.11% | 65.51% |
Shares Outstanding (Basic) | 11 | 11 | 12 | 12 | 12 | 13 |
Shares Outstanding (Diluted) | 12 | 12 | 12 | 12 | 13 | 13 |
Shares Change | -0.72% | -2.55% | -2.98% | -2.95% | -2.57% | -1.70% |
EPS (Basic) | 0.87 | 0.80 | 0.63 | 0.54 | 0.44 | 0.50 |
EPS (Diluted) | 0.85 | 0.78 | 0.62 | 0.53 | 0.43 | 0.49 |
EPS Growth | 20.37% | 27.11% | 16.01% | 22.07% | -10.86% | 68.28% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 11.46 | 8.97 | 8.63 | 5 | 4.9 | 4.59 |
Free Cash Flow Per Share | 0.99 | 0.78 | 0.73 | 0.41 | 0.39 | 0.36 |
Dividend Per Share | 0.210 | 0.200 | 0.180 | 0.160 | 0.040 | - |
Dividend Growth | 10.53% | 11.11% | 12.50% | 300.00% | - | - |
Gross Margin | 73.38% | 76.57% | 79.52% | 81.03% | 81.85% | 79.10% |
Operating Margin | 23.75% | 26.00% | 26.21% | 23.65% | 25.00% | 28.59% |
Profit Margin | 17.72% | 20.93% | 20.75% | 20.45% | 19.55% | 21.95% |
Free Cash Flow Margin | 20.58% | 20.83% | 24.64% | 15.81% | 17.55% | 16.04% |
EBITDA | 14.88 | 11.89 | 9.6 | 7.63 | 7.26 | 8.47 |
EBITDA Margin | 26.73% | 27.63% | 27.41% | 24.15% | 26.01% | 29.60% |
D&A For EBITDA | 1.66 | 0.7 | 0.42 | 0.16 | 0.28 | 0.29 |
EBIT | 13.22 | 11.19 | 9.18 | 7.47 | 6.98 | 8.18 |
EBIT Margin | 23.75% | 26.00% | 26.21% | 23.65% | 25.00% | 28.59% |
Effective Tax Rate | 26.26% | 25.09% | 25.68% | 24.30% | 26.54% | 25.03% |